Released on = November 30, 2005, 2:35 am

Press Release Author = Anna Oderda

Industry = Biotech

Press Release Summary = Research Will Focus on Potential New Treatments for
Psoriasis and Restenosis

Press Release Body = Colleretto Giacosa (Turin) Italy, and Milan Italy, November 30,
2005- Bio3 Research s.r.l., and Creabilis Therapeutics S.p.A. today announced agreements with Cephalon, Inc. to evaluate the research compound K252a for its potential to topically treat psoriasis and for potential use in the prevention and
treatment of restenosis. Creabilis Therapeutics owns patent applications covering
K252a-based products for the treatment of psoriasis.

Bio3 Research and Creabilis Therapeutics co-own a patent application covering the
use of K252a compound to prevent and treat restenosis and other cardiovascular disorders. Cephalon has proprietary rights in certain production processes for the compound. Also, with respect to the prevention and treatment of restenosis, Bio3 Research retains the right to collaborate with third parties in combining K252a with drugeluting stents. Other terms of the agreements were not disclosed.

Under the agreement, Cephalon has an exclusive option to develop and commercialize
K252a-based products that may result from research performed by Creabilis Therapeutics and Bio3 Research. "This agreement with Cephalon is a great opportunity for Creabilis Therapeutics because it enables us to accelerate the development process of this promising compound," said Dr. Silvano Fumero, the company's CEO. "We expect to file the INDs by the end of 2006."

Francesco Paolo Pilato, President and CEO of Bio3 Research, said, "We are delighted
to have entered into this agreement with Cephalon, and we believe it is a great opportunity for our company to accelerate the ongoing development process at Creabilis Therapeutics. This research is part of Bio3's strong IP position in the field of HMGB1-related cardiovascular disorders."

About Creabilis Therapeutics S.p.A.
Creabilis Therapeutics S.p.A. is a privately owned drug-discovery and development
company, founded in 2003 and located in the Bioindustry Park of Canavese, near Turin. The company's activity focuses mainly on DNA-binding proteins, such as HMGB1, as pharmacological targets for novel classes of inhibitors/antagonists to be developed as therapeutics. This portfolio is complemented by selected projects in related biochemical or clinical areas. Additional information on Creabilis Therapeutics can be obtained from
www.creabilistherapeutics.com or by e-mail: info@creabilistherapeutics.com

About Bio3 Research s.r.l.
Bio3 Research s.r.l., an Italian company founded in 2001, has headquarters in Milan
and an office at the Bioindustry Park of Canavese (Turin). Bio3 Research works with research institutions, individual scientists and early-stage companies to identify, protect and exploit commercially promising intellectual property in the life sciences. Such assistance may include pre-clinical development and negotiation of strategic industrial
partnerships. Bio3 Research's activity focuses mainly on the field of HMBG1-related
cardiovascular disorders and use of HMGB1 and its fragments in connective tissue regeneration. Other fields of interest include skin and renal diseases. Additional information on Bio3 Research can be obtained from www.bio3research.com
or by e-mail: info@bio3research.com

info@bio3research.com info@creabilistherapeutics.com



Web Site = http://www.creabilistherapeutics.com

Contact Details = Creabilis Therapeutics SpA
via Ribes 5
10010 Colleretto Giacosa (TO)
Italy

email: aoderda@creabilistherapeutics.com